Pandemic Influenza Clinical Trial
Official title:
A Prospective Study to Examine the Effectiveness and Safety of Antivirals in Volunteers Who Receive Short-term Prophylaxis Against Pandemic Influenza.
This aim of this project is to evaluate the efficacy of neuraminidase inhibitors as short-term prophylaxis against pandemic influenza infection in people who have close familial contact with the disease. The study is observational only. The primary measure used in this study will be the incidence of symptomatic pandemic influenza in patients receiving prophylaxis. Seroconversion to pandemic influenza, the incidence of adverse events and the relative effectiveness of oseltamivir and zanamivir prophylaxis will also be examined. This project will commence upon pandemic influenza being declared in Australia, Hong Kong or Singapore. Data will be analysed as quickly as possible to help inform the continued use of neuraminidase inhibitor therapy as a cornerstone of the public health agency response to pandemic influenza.
The aim of this study is to
1. Describe the effectiveness of short-term prophylaxis against symptomatic pandemic
influenza infection
2. Describe the safety of short-term prophylaxis
3. Describe the seroconversion rate against pandemic influenza among recipients of
short-term prophylaxis
The study is an open label prospective cohort study. Contact group members of people with
diagnosed influenza who are recommended to receive NA inhibitor prophylaxis for short
periods of time will be enrolled following provision of informed consent. Each episode of
short-term prophylaxis will be recorded separately.
By design it is hoped that volunteers in this study who develop symptoms and signs of
pandemic influenza infection will be enrolled in the Index Case (PIPET A) protocol with
follow-up as required.
;
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00971542 -
Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine (Egg-Derived) in Healthy Subjects From 6 Months to 17 Years of Age
|
Phase 3 | |
| Completed |
NCT00976469 -
A/H1N1 Immunogenicity and Safety in Infants, Children and Adolescents
|
Phase 1/Phase 2 | |
| Completed |
NCT00535665 -
Safety and Immunogenicity of an Inactivated Pandemic Influenza Vaccine
|
Phase 2 | |
| Completed |
NCT00950456 -
Observational Study to Assess Safety of H1N1 Pandemic Influenza Vaccine
|
N/A | |
| Completed |
NCT00908687 -
A/H5N1/LT Dose Ranging Study
|
Phase 2 | |
| Completed |
NCT00783926 -
Phase 1 Study of a H5N1 Influenza Vaccine (Reverse Genetic Reassortant)
|
Phase 1 | |
| Completed |
NCT00519389 -
Safety, Reactogenicity and Immunogenicity of an H5N1 VLP
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06046092 -
H7HLAII DNA Influenza Vaccine
|
Phase 1 | |
| Completed |
NCT01640691 -
Immunogenicity and Safety of Pandemic Influenza Vaccine in Healthy Adults
|
Phase 1/Phase 2 | |
| Completed |
NCT01053143 -
Study of Swine-Origin A/H1N1 Influenza Non-Adjuvanted Vaccine in Healthy Adults in India
|
Phase 3 | |
| Completed |
NCT00660257 -
Safety and Immunogenicity of Booster Dose of An Inactivated,Adjuvanted Whole-Virion Pandemic Influenza(H5N1)Vaccine
|
Phase 1 | |
| Completed |
NCT00457509 -
Safety and Immunogenicity of H5N1 Adjuvanted, Inactivated, Split-Virion Pandemic Influenza Vaccine in Healthy Adults
|
Phase 1 | |
| Completed |
NCT00971906 -
Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age
|
Phase 3 | |
| Completed |
NCT00959465 -
A/H1N1 Immunogenicity and Safety in Adults
|
Phase 1/Phase 2 | |
| Completed |
NCT00970177 -
Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age
|
Phase 3 | |
| Completed |
NCT00971100 -
Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects From 6 Months to 17 Years of Age
|
Phase 3 | |
| Completed |
NCT00532792 -
A/H5N1 Dose Ranging Study With Adjuvant Patch
|
Phase 1 | |
| Withdrawn |
NCT00640211 -
A Prospective Study to Examine the Effectiveness and Safety of Neuraminidase Inhibitors in Volunteers Who Receive Long-term Prophylaxis Against Pandemic Influenza: PIPET B
|
N/A | |
| Withdrawn |
NCT00640302 -
A Prospective Study to Examine the Effectiveness and Safety of Neuraminidase Inhibitors in Index Cases With Presumed Pandemic Influenza
|
N/A |